Welcome to our dedicated page for Innovex International SEC filings (Ticker: INVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Innovex International, Inc. (NYSE: INVX), a Houston-based energy industrial platform operating in the Oil & Gas Equipment & Services industry. Innovex files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with any other required disclosures.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and other material events. For example, Innovex has filed 8-Ks to furnish earnings press releases for quarters ended March 31, June 30, and September 30, 2025, and to report matters such as the planned sale and subsequent closing of a legacy facility and board-related changes. These filings often incorporate press releases that discuss revenue, net income, cash flow, Adjusted EBITDA, Free Cash Flow, and Return on Capital Employed, along with reconciliations of non-GAAP measures to GAAP metrics.
Through this SEC filings page, users can review Innovex’s 10-K and 10-Q reports for detailed information on its well-centric product portfolio, risk factors, segment performance, and capital allocation approach, as described by the company. Form 4 and other ownership filings, when available, can be used to monitor transactions by directors, officers, and significant shareholders.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, highlight notable changes from prior periods, and clarify technical language. Real-time updates from the SEC’s EDGAR system ensure that new Innovex filings, including earnings-related 8-Ks and other material disclosures, are added promptly so investors can quickly see how the company’s regulatory reporting aligns with its public commentary on strategy, M&A, and financial performance.
Innovex International director Sedita Angie reported a stock grant. On this Form 4, Sedita received 5,465 shares of Innovex International, Inc. common stock as a grant or award at no cost. After this acquisition, Sedita directly holds a total of 29,881 common shares.
Innovex International, Inc. director John Lovoi received a stock award of 5,465 shares of common stock on February 27, 2026, recorded as a grant or other acquisition at a stated price of $0.00 per share. After this award, his directly held common stock ownership increased to 101,427 shares.
Reddout Mark reported acquisition or exercise transactions in this Form 4 filing.
Innovex International, Inc. reported that President of North America Mark Reddout received a grant of 18,975 shares of common stock on February 27, 2026. The award was recorded at a price of $0.00 per share, bringing his directly held common stock to 148,411 shares after the transaction.
Black Bonnie S. reported acquisition or exercise transactions in this Form 4 filing.
Innovex International, Inc. director Bonnie S. Black received a grant of 5,465 shares of common stock on February 27, 2026 at no stated purchase price. Following this award, she directly holds a total of 35,844 common shares.
Reed Kendal reported acquisition or exercise transactions in this Form 4 filing.
Innovex International, Inc. reported that Chief Financial Officer Reed Kendal received a grant of 18,975 shares of common stock on February 27, 2026 as a stock award with no purchase price. Following this award, his directly owned holdings total 217,832 common shares.
Innovex International’s major shareholder group updated its ownership after a large secondary stock sale. Selling stockholders agreed to sell 5,750,000 shares of common stock at $25.75 per share, and the underwriters fully exercised a 30-day option for another 862,500 shares.
The selling stockholders received $24.59125 per share, reflecting underwriting discounts. As part of the same transaction, Innovex repurchased 575,000 of these shares under its existing buyback program. After these moves, Amberjack-related entities and affiliates may be deemed to beneficially own 22,757,322 shares, or 33.2% of the 68,563,690 shares outstanding as of February 27, 2026.
Amberjack-affiliated investment funds sold 6,612,500 shares of Innovex International common stock in an underwritten secondary offering. The shares were sold at a public offering price of $25.75 per share, and the selling funds received $24.59125 per share after underwriting discounts.
The transactions were reported as indirect sales by entities including Amberjack Capital Fund II, Innovex Co-Invest Fund II, Innovex Co-Invest Fund, Intervale Capital Fund II, Intervale Capital Fund II-A, and Intervale Capital Fund III. Footnotes state that Amberjack Management and related general partners may be deemed beneficial owners, while managing partner Jason Turowsky disclaims beneficial ownership beyond his economic interest.
Innovex International, Inc. reported that investment funds affiliated with Amberjack Capital Partners sold a total of 6,612,500 shares of Innovex common stock in open-market-style transactions tied to an underwritten secondary offering. The shares were sold at a public price of $25.75 per share, with the funds receiving $24.59125 per share after underwriting discounts. Individual transactions included 4,902,244 shares sold by Amberjack Capital Fund II, L.P., 1,144,635 shares by Innovex Co-Invest Fund II, L.P., 271,279 shares by Innovex Co-Invest Fund, L.P., and smaller blocks by Intervale Capital Fund II, L.P., Intervale Capital Fund II-A, L.P., and Intervale Capital Fund III, L.P. After these sales, Amberjack Capital Fund II, L.P. held 16,871,374 Innovex shares, while Innovex Co-Invest Fund II, L.P. held 3,939,330 shares and Innovex Co-Invest Fund, L.P. held 933,624 shares.
Innovex International, Inc. supported a secondary share sale by major stockholders and simultaneously executed a share repurchase. Affiliates of Amberjack Capital Partners sold 5,750,000 shares of common stock at $25.75 per share, and underwriters exercised a 30-day option for an additional 862,500 shares. Innovex did not sell any shares or receive proceeds from this Offering. Instead, it repurchased 575,000 shares from the underwriters for about $14.1 million under its existing buyback program, leaving roughly $76.6 million available for future repurchases. A committee of independent directors approved the transaction, and both the Offering and repurchase closed on February 27, 2026.
Innovex International, Inc. is registering 5,750,000 shares of common stock for resale by the selling stockholders.
The company will not receive proceeds from these sales; the selling stockholders will receive the net proceeds at a public offering price of $25.75 per share. The underwriters’ discount is $1.15875 per share. Innovex intends, subject to the offering’s completion, to purchase the lesser of 10% (which would be 575,000 shares) and $15,000,000 of the shares being sold. The underwriters have an option to purchase up to 862,500 additional shares. The last reported sale price on the NYSE was $28.90 per share as of February 24, 2026.